Skip to main content
Premium Trial:

Request an Annual Quote

Aviva to Make Antibodies for ISB's Liver Toxicity Biomarker Program

NEW YORK (GenomeWeb News) - Aviva Systems Biology will produce antibodies that the Institute for Systems Biology will use to identify liver toxicity biomarkers, Aviva said Wednesday.
 
Under the terms of the collaborative agreement, Aviva will develop and produce the antibodies from a list of proteins provided by the ISB.
 
ISB will then assess the efficacy of these antibodies and will use them to find biomarker proteins that work as early liver toxicity biomarkers.
 
Aviva said the antibodies will be used in surface plasmon resonance imaging, a method of detecting proteins at density levels lower than is currently possible with mass spectrometry and other technologies.
 
Aviva said it has an inventory of more than 12,000 target peptide-specific antibodies that represent over 4,000 human and mouse targets.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.